ClinicalTrials.gg
CompletedNCT00667355Updated Jan 26, 2012Results posted

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

A Phase 3 interventional study of adalimumab in Ankylosing Spondylitis, sponsored by Abbott. Completed at 19 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.

Enrollment
16th of 19
41 · median 80
Started
2008
with 1 other
Phase 3
7 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
5 of 19
Abbott

Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 16th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 5th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing adalimumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis

Read the detailed description

It is reported that the prevalence of Ankylosing Spondylitis (AS) in Japanese patients is extremely lower than that of Caucasians; therefore, a controlled, double-blind study with similar sample size in Western studies for active AS in Japan was not able to be conducted. As a result, this study was conducted with an open-label design to investigate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active AS. The inclusion criteria and primary endpoint measurement (Achieving Assessment in Ankylosing Spondylitis 20 at Week 12) were designed the same as the Western studies for active AS in consideration with the confirmation of Western data. Treatment with adalimumab was to be continued until the approval of adalimumab for AS in Japanese subjects with active AS.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who meets the definition of Ankylosing Spondylitis based on the Modified New York Criteria, has a diagnosis of active Ankylosing Spondylitis and has had an inadequate response to or intolerance to one or more nonsteroidal anti-inflammatory drugs

Exclusion criteria

Exclusion Criteria:

  • History of cancer, lymphoma, leukemia or lymphoproliferative disease, active TB,
  • Previously received anti-TNF therapy
  • Spinal surgery or joint surgery involving joints to be assessed within 2 months prior to the Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    40 mg or 80 mg every other week, subcutaneous

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

    Time frame: Week 12

Secondary outcomes

  1. Number of Subjects Achieving ASAS 20

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  2. Number of Subjects Achieving ASAS 50

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = at least 50% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  3. Number of Subjects Achieving ASAS 70

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = at least 70% improvement (vs. baseline) and an absolute improvement ≥ 30 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  4. Number of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50)

    BASDAI is a validated self assessment tool used to determine disease activity in subjects with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  5. Mean Change From Baseline in Patient's Global Assessment of Disease Activity

    Subject's assessment of disease activity using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = none and 100 = severe).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  6. Mean Change From Baseline in Total Back Pain

    Subject assessed his/her back pain by using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = most severe pain).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  7. Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    BASFI is a validated self assessment tool that determines the degree of functional limitation in AS subjects. Utilizing a VAS of 0-100 mm (0=easy, 100=impossible), subjects answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  8. Mean Change From Baseline in C-Reactive Protein (CRP)

    CRP is a marker of inflammation and measured in mg/dL. A higher level is consistent with inflammation.

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  9. Number of Subjects Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.

    ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains (each domain measured on a 0 - 100 scale \[0 = no disease activity; 100 = high disease activity\]).

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  10. Number of Subjects Achieving Assessment in Ankylosing Spondylitis 40 (ASAS 40)

    ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = at least 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening in remaining domain.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  11. Number of Subjects Achieving Assessment in Ankylosing Spondylitis Partial Remission

    Partial remission is defined as a score of less than 20 units (on a scale of 0-100; 0=no disease activity and 100=high disease activity) in each of the 4 Assessments in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation.

    Time frame: Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  12. Mean Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total score ranging from 0 to 10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  13. Mean Change From Baseline in Chest Expansion

    Chest expansion is the difference in centimeters between full expiration and full inspiration, measured at the 4th inter-costal space. An increase in chest expansion represents improvement.

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  14. Mean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  15. Mean Change From Baseline in Nocturnal Pain

    Nocturnal pain assessed by subjects using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = worst possible pain).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  16. Mean Change From Baseline in Swollen Joint Count for 44 Joints (SJC 44)

    The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  17. Mean Change From Baseline in Tender Joint Count for 46 Joints (TJC 46)

    The number of tender or painful joints among 23 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender or painful joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender or painful joints) to 46 (worst possible score; all joints tender or painful).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

  18. Mean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).

    Time frame: Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit

07

Results

Posted Aug 11, 2010

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started41
Completed30
Not completed11
Withdrew: Adverse event5
Withdrew: Lost to follow-up1
Withdrew: Other reason was not specified5

Outcome measures

PrimaryNumber of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Time frame:
Week 12
Reported as:
Number · Subjects
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12
SubjectsAdalimumab
Non-responder imputation (NRI), N = 4130
Last Observation Carried Forward (LOCF), N = 4130
Observed Cases, N = 4030
SecondaryNumber of Subjects Achieving ASAS 20

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving ASAS 20
SubjectsAdalimumab
Week 1230
Week 2430
Week 4832
Week 7232
Week 9627
Week 12021
Final Visit32
SecondaryNumber of Subjects Achieving ASAS 50

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = at least 50% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving ASAS 50
SubjectsAdalimumab
Week 1223
Week 2426
Week 4826
Week 7225
Week 9619
Week 12017
Final Visit27
SecondaryNumber of Subjects Achieving ASAS 70

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = at least 70% improvement (vs. baseline) and an absolute improvement ≥ 30 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving ASAS 70
SubjectsAdalimumab
Week 1213
Week 2416
Week 4818
Week 7217
Week 9615
Week 12013
Final Visit19
SecondaryNumber of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50)

BASDAI is a validated self assessment tool used to determine disease activity in subjects with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50)
SubjectsAdalimumab
Week 1227
Week 2426
Week 4825
Week 7228
Week 9622
Week 12018
Final Visit29
SecondaryMean Change From Baseline in Patient's Global Assessment of Disease Activity

Subject's assessment of disease activity using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = none and 100 = severe).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · mm on scale
Mean Change From Baseline in Patient's Global Assessment of Disease Activity
mm on scaleAdalimumab
Week 12-34.6 (-42.80 to -26.33)
Week 24-37.3 (-45.99 to -28.69)
Week 48-39.5 (-47.52 to -31.51)
Week 72-39.7 (-48.14 to -31.32)
Week 96-37.1 (-45.96 to -28.34)
Week 120-40.1 (-48.61 to -31.53)
Final Visit-40.6 (-48.81 to -32.32)
SecondaryMean Change From Baseline in Total Back Pain

Subject assessed his/her back pain by using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = most severe pain).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · mm on scale
Mean Change From Baseline in Total Back Pain
mm on scaleAdalimumab
Week 12-35.6 (-43.68 to -27.59)
Week 24-37.0 (-45.05 to -28.85)
Week 48-38.6 (-46.68 to -30.53)
Week 72-39.3 (-47.53 to -31.01)
Week 96-36.4 (-44.33 to -28.40)
Week 120-39.2 (-46.98 to -31.36)
Final Visit-40.2 (-47.80 to -32.64)
SecondaryMean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

BASFI is a validated self assessment tool that determines the degree of functional limitation in AS subjects. Utilizing a VAS of 0-100 mm (0=easy, 100=impossible), subjects answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · mm on scale
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
mm on scaleAdalimumab
Week 12-19.4 (-24.49 to -14.34)
Week 24-20.5 (-25.84 to -15.08)
Week 48-21.9 (-28.39 to -15.51)
Week 72-22.2 (-29.44 to -14.89)
Week 96-22.1 (-28.72 to -15.54)
Week 120-21.8 (-28.07 to -15.51)
Final Visit-21.6 (-27.65 to -15.49)
SecondaryMean Change From Baseline in C-Reactive Protein (CRP)

CRP is a marker of inflammation and measured in mg/dL. A higher level is consistent with inflammation.

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · mg/dL
Mean Change From Baseline in C-Reactive Protein (CRP)
mg/dLAdalimumab
Week 12-1.2 (-1.60 to -0.83)
Week 24-1.3 (-1.76 to -0.89)
Week 48-1.4 (-1.78 to -0.95)
Week 72-1.3 (-1.74 to -0.83)
Week 96-1.4 (-1.84 to -0.94)
Week 120-1.3 (-1.76 to -0.76)
Final Visit-1.2 (-1.67 to -0.64)
SecondaryNumber of Subjects Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.

ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains (each domain measured on a 0 - 100 scale \[0 = no disease activity; 100 = high disease activity\]).

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.
SubjectsAdalimumab
Week 1228
Week 2429
Week 4831
Week 7228
Week 9625
Week 12020
Final Visit29
SecondaryNumber of Subjects Achieving Assessment in Ankylosing Spondylitis 40 (ASAS 40)

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = at least 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening in remaining domain.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 40 (ASAS 40)
SubjectsAdalimumab
Week 1226
Week 2426
Week 4827
Week 7228
Week 9624
Week 12018
Final Visit26
SecondaryNumber of Subjects Achieving Assessment in Ankylosing Spondylitis Partial Remission

Partial remission is defined as a score of less than 20 units (on a scale of 0-100; 0=no disease activity and 100=high disease activity) in each of the 4 Assessments in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation.

Time frame:
Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Number · Subjects
Number of Subjects Achieving Assessment in Ankylosing Spondylitis Partial Remission
SubjectsAdalimumab
Week 1215
Week 2416
Week 4817
Week 7220
Week 9615
Week 12013
Final Visit19
SecondaryMean Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total score ranging from 0 to 10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · units on scale
Mean Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
units on scaleAdalimumab
Week 12-0.4 (-0.79 to -0.02)
Week 24-0.5 (-0.90 to -0.17)
Week 48-0.6 (-1.07 to -0.23)
Week 72-0.5 (-0.95 to -0.06)
Week 96-0.6 (-1.03 to -0.13)
Week 120-0.7 (-1.09 to -0.22)
Final Visit-0.6 (-1.00 to -0.21)
SecondaryMean Change From Baseline in Chest Expansion

Chest expansion is the difference in centimeters between full expiration and full inspiration, measured at the 4th inter-costal space. An increase in chest expansion represents improvement.

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · cm
Mean Change From Baseline in Chest Expansion
cmAdalimumab
Week 120.7 (0.30 to 1.03)
Week 240.4 (0.16 to 0.66)
Week 480.8 (0.40 to 1.17)
Week 721.0 (0.56 to 1.46)
Week 960.6 (0.19 to 1.11)
Week 1201.1 (0.55 to 1.72)
Final Visit1.2 (0.54 to 1.80)
SecondaryMean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · units on a scale
Mean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
units on a scaleAdalimumab
Week 12-1.0 (-1.71 to -0.39)
Week 24-1.1 (-1.76 to -0.53)
Week 48-1.3 (-1.90 to -0.74)
Week 72-1.1 (-1.72 to -0.48)
Week 96-1.4 (-1.98 to -0.85)
Week 120-1.4 (-1.96 to -0.77)
Final Visit-1.4 (-1.96 to -0.77)
SecondaryMean Change From Baseline in Nocturnal Pain

Nocturnal pain assessed by subjects using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = worst possible pain).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · mm on scale
Mean Change From Baseline in Nocturnal Pain
mm on scaleAdalimumab
Week 12-30.0 (-39.71 to -20.29)
Week 24-31.7 (-41.92 to -21.54)
Week 48-35.8 (-45.04 to -26.61)
Week 72-34.6 (-43.45 to -25.77)
Week 96-33.4 (-43.14 to -23.69)
Week 120-35.0 (-44.10 to -25.85)
Final Visit-35.3 (-44.52 to -26.07)
SecondaryMean Change From Baseline in Swollen Joint Count for 44 Joints (SJC 44)

The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · SJC
Mean Change From Baseline in Swollen Joint Count for 44 Joints (SJC 44)
SJCAdalimumab
Week 12-1.1 (-1.91 to -0.38)
Week 24-1.1 (-1.81 to -0.34)
Week 48-1.1 (-1.97 to -0.32)
Week 72-1.3 (-2.17 to -0.37)
Week 96-1.2 (-1.99 to -0.44)
Week 120-1.2 (-2.01 to -0.43)
Final Visit-1.2 (-1.94 to -0.40)
SecondaryMean Change From Baseline in Tender Joint Count for 46 Joints (TJC 46)

The number of tender or painful joints among 23 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender or painful joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender or painful joints) to 46 (worst possible score; all joints tender or painful).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · TJC
Mean Change From Baseline in Tender Joint Count for 46 Joints (TJC 46)
TJCAdalimumab
Week 12-1.5 (-3.86 to 0.94)
Week 24-1.4 (-3.66 to 0.87)
Week 48-1.3 (-3.60 to 0.96)
Week 72-1.6 (-4.00 to 0.88)
Week 96-1.6 (-3.63 to 0.46)
Week 120-1.6 (-3.69 to 0.56)
Final Visit-1.6 (-3.69 to 0.56)
SecondaryMean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).

Time frame:
Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit
Reported as:
Mean · units on scale
Mean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire
units on scaleAdalimumab
PCS Week 129.6 (6.81 to 12.40)
PCS Week 2410.6 (7.51 to 13.67)
PCS Week 4811.4 (8.69 to 14.06)
PCS Week 7211.3 (8.29 to 14.30)
PCS Week 9612.3 (9.25 to 15.37)
PCS Week 12012.1 (9.07 to 15.19)
PCS Final Visit12.6 (9.75 to 15.53)
MCS Week 127.0 (3.07 to 10.87)
MCS Week 247.0 (3.62 to 10.34)
MCS Week 486.1 (2.52 to 9.59)
MCS Week 726.7 (2.94 to 10.53)
MCS Week 965.8 (2.55 to 9.09)
MCS Week 1206.1 (2.63 to 9.59)
MCS Final Visit5.9 (2.44 to 9.42)

Adverse events

Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—6/41 (14.6%)41/41 (100%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
CataractEye disorders2/41
ThrombocytopeniaBlood and lymphatic system disorders1/41
Intervertebral discitisInfections and infestations1/41
OsteomyelitisInfections and infestations1/41
PneumoniaInfections and infestations1/41
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/41
PeriodontitisGastrointestinal disorders1/41
Septic shockInfections and infestations1/41
AdenomyosisReproductive system and breast disorders1/41
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/41
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAdalimumab
NasopharyngitisInfections and infestations22/41
Hepatic function abnormalHepatobiliary disorders9/41
DiarrhoeaGastrointestinal disorders8/41
Upper respiratory tract infectionInfections and infestations8/41
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders8/41
Upper respiratory tract infectionInfections and infestations7/41
Injection site erythemaGeneral disorders6/41
Ankylosing spondylitisMusculoskeletal and connective tissue disorders6/41
ContusionInjury, poisoning and procedural complications6/41
HeadacheNervous system disorders5/41

Baseline characteristics

Age, Customized
Age, Customized(subjects)Adalimumab
<40 years25
Between 40 and 65 years16
>65 years0
Age Continuous
Age Continuous(years)Adalimumab
Mean37.2 ± 12.17
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female9
Male32
Region of Enrollment
Region of Enrollment(subjects)Adalimumab
Japan41
08

Study locations

19 sites
  • Site Reference # / Investigator 46791
    Aichi, Japan
  • Site Reference # / Investigator 46789
    Fukui, Japan
  • Site Reference # / Investigator 46798
    Fukuoka, Japan
  • Site Reference # / Investigator 46799
    Fukuoka, Japan
  • Site Reference # / Investigator 46796
    Hiroshima, Japan
  • Site Reference # / Investigator 46782
    Hokkaido, Japan
  • Site Reference # / Investigator 7297
    Hokkaido, Japan
  • Site Reference # / Investigator 46795
    Hyogo, Japan
  • Site Reference # / Investigator 46797
    Kagawa, Japan
  • Site Reference # / Investigator 46787
    Kanagawa, Japan
  • Site Reference # / Investigator 46790
    Nagano, Japan
  • Site Reference # / Investigator 46793
    Osaka, Japan
  • Site Reference # / Investigator 46794
    Osaka, Japan
  • Site Reference # / Investigator 46783
    Saitama, Japan
  • Site Reference # / Investigator 46784
    Saitama, Japan
  • Site Reference # / Investigator 46792
    Shiga, Japan
  • Site Reference # / Investigator 46785
    Tokyo, Japan
  • Site Reference # / Investigator 46786
    Tokyo, Japan
  • Site Reference # / Investigator 46788
    Toyama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2008
First posted
Apr 28, 2008
Start
Feb 2008
Primary completionActual
May 2009
CompletionActual
Jan 2011
Results first posted
Aug 11, 2010
Last update
Jan 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00667355
Lead sponsor
Abbott
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Apr 28, 2008
Start date
Feb 2008
Primary completion
May 2009
Completion
Jan 2011
Results posted
Aug 11, 2010
Last update
Jan 26, 2012

Study contacts

Hideyuki Hashiba, BS
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion